fasudil reformulated (RT1968) / Raya Therap - LARVOL DELTA

Raya Therapeutic Announces Oral Presentation and Poster at International Symposium on ALS/MND in Montreal December 6-8 (EIN News) - "Raya Therapeutic Inc...announces the presentation of the Phase 2 ROCK-ALS study data for its lead compound, fasudil (RT1968) for the treatment of Amyotrophic Lateral Sclerosis (ALS) by Dr. Paul Lingor (Principal Investigator) on Friday, December 6th at the 35th International Symposium on ALS/MND in Montreal...The company would also like to announce a poster presentation...entitled: 'The novel combination of 2 clinical-stage molecules demonstrates a beneficial effect in preclinical models of ALS.' Raya is also developing 2 novel small molecules, RT1972 and RT1999, each of which have neuroprotective effects in ALS preclinical models...Raya believes that this is the first presentation of a combination of two new chemical entities across multiple preclinical models of ALS."

P2 data • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders

Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients (PRNewswire) - P2 | N=120 | ROCK-ALS (NCT03792490) | "Raya Therapeutic Inc...is pleased to announce supportive clinical data for its lead compound, fasudil...as disclosed in a conference abstract for the ENCALS meeting by the investigators of the ROCK-ALS Phase 2 clinical trial...In the intention-to-treat population (118 participants), safety and tolerability were not significantly different between groups. In the secondary outcomes, MUNIX showed a significantly reduced decline with Fasudil 60 mg at 26 and 90 days, and for Fasudil 30 mg at 90 days after treatment initiation. In addition, there was a directional difference in a slower loss of SVC favoring the 60 mg of fasudil treatment at day 26, which was statistically significant in a post-hoc subgroup analysis of females at all time points, as stated in the conference abstract."

P2 data • Amyotrophic Lateral Sclerosis • CNS Disorders